Anavex Life Sciences Corp.
HealthcareNASDAQ:AVXL · NASDAQ Global Select
+$0.00 today
Vol 1.20M · Avg 1.38M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$39.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.46, tying the income statement back to per-share earnings.
Income Statement
Annual data · 0 periods
| Metric |
|---|
| Revenue |
| Cost of Revenue |
| Gross Profit |
| Gross Margin |
| Research & Development |
| Selling, General & Admin |
| Operating Expenses |
| Depreciation & Amortization |
| EBITDA |
| EBITDA Margin |
| Operating Income |
| Operating Margin |
| Interest Income |
| Interest Expense |
| Other Income / Expenses |
| Income Before Tax |
| Pre-Tax Margin |
| Income Tax Expense |
| Net Income |
| Net Margin |
| EPS (Basic) |
| EPS (Diluted) |
| Weighted Avg Shares |
| Weighted Avg Shares (Diluted) |
Competitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.37B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.38B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.19B
Absci Corporation
NASDAQ:ABSI
$1.06B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Astria Therapeutics, Inc.
ATXS
$718.13M
Valneva SE
NASDAQ:VALN
$507.78M
Arvinas, Inc.
NASDAQ:ARVN
$489.07M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$484.08M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does AVXL generate?
Anavex Life Sciences Corp. (AVXL) reported $0.00 of revenue in fiscal 2025.
Is AVXL profitable?
Anavex Life Sciences Corp. (AVXL) reported -$46,377,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.